Immune Spatial Features of Guselkumab Cutaneous Response

Description

This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Conditions

Psoriasis of Scalp

Talk to us

Study Overview

On this page

Study Details

Study overview

This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Immune Spatial Features of Guselkumab Cutaneous Response

Immune Spatial Features of Guselkumab Cutaneous Response

Condition
Psoriasis of Scalp
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California San Francisco, San Francisco, California, United States, 94115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. taking systemic immunosuppressives in the last 4 weeks
  • 2. pregnancy
  • 3. severe immunodeficiency (either from genetic or infectious causes).
  • 4. tuberculosis or other active serious infection
  • 5. active systemic malignancy.
  • 6. breast-feeding
  • 7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  • 8. Males who are trying to conceive

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of California, San Francisco,

Raymond Cho, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2026-06-30